Across TCGA pan-cancer cohorts, ANKRD49 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ANKRD49 data layer compared with 21 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ANKRD49 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ANKRD49 expression acts as an unfavorable survival marker.
LUAD, SKCM, and UCEC are the cancer types where ANKRD49 Mutation most reproducibly stratifies survival.